1. Home
  2. LXEH vs NOTV Comparison

LXEH vs NOTV Comparison

Compare LXEH & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixiang Education Holding Co. Ltd.

LXEH

Lixiang Education Holding Co. Ltd.

HOLD

Current Price

$0.22

Market Cap

6.5M

Sector

Real Estate

ML Signal

HOLD

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.36

Market Cap

12.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEH
NOTV
Founded
2001
1974
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
12.7M
IPO Year
2020
1997

Fundamental Metrics

Financial Performance
Metric
LXEH
NOTV
Price
$0.22
$0.36
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
566.0K
538.8K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
49.64
EPS
N/A
N/A
Revenue
N/A
$547,656,000.00
Revenue This Year
N/A
$5.28
Revenue Next Year
N/A
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
511.19
52 Week Low
$0.18
$0.25
52 Week High
$50.08
$3.35

Technical Indicators

Market Signals
Indicator
LXEH
NOTV
Relative Strength Index (RSI) 47.96 47.63
Support Level $0.19 $0.26
Resistance Level $0.28 $0.65
Average True Range (ATR) 0.03 0.05
MACD 0.00 0.02
Stochastic Oscillator 17.16 46.95

Price Performance

Historical Comparison
LXEH
NOTV

About LXEH Lixiang Education Holding Co. Ltd.

Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: